New Rochelle, June 1, 2016-Researchers have discovered three new inhibitors of insulin-regulated aminopeptidase (IRAP), compounds shown to improve cognitive functions in animal models of human disorders. The new inhibitors are able to block human IRAP at low concentrations with rapid reversibility, as described in a study published in ASSAY and Drug Development Technologies, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the ASSAY and Drug Development Technologies website until July 1, 2016.
In the article "Identification of Drug-Like Inhibitors of Insulin-Regulated Aminopeptidase Through Small Molecule Screening," Karin Engen and coauthors from Uppsala University and Karolinska Institutet (Solna), Sweden, and Vrije Universiteit Brussel, Brussels, Belgium, report on the high throughput screening method they used to test a diverse library of 10,500 compounds for activity against IRAP. The rapid, automated, enzymatic assay led to the identification of 23 active compounds. Rigorous characterization of these actives reduced the number of compounds of particular interest to three, and these served as the starting points for the development of small molecule-based IRAP inhibitors to take into preclinical testing.
"The paper by Engen et al. describes exemplary work successfully executing a carefully planned strategy to identify high-value hits from high-throughput screens," says ASSAY and Drug Development Technologies Editor-in-Chief Andrew D. Napper, PhD, Associate Director, Nemours Center for Childhood Cancer Research, Head - High Throughput Screening/Drug Discovery Laboratory, and Senior Research Scientist, Nemours/A.I. duPont Hospital for Children (Wilmington, DE). "Using high-throughput screening and hit confirmation, the authors identified and efficiently prioritized inhibitors of insulin-regulated aminopeptidase, which hold promise for the improvement of cognitive functions in animal models and advancement into clinical testing."
About the Journal
ASSAY and Drug Development Technologies is an authoritative peer-reviewed journal published 10 times a year online with open access options and in print. Led by Editor-in-Chief Andrew D. Napper, PhD, Associate Director, Nemours Center for Childhood Cancer Research, Head - High Throughput Screening/Drug Discovery Laboratory, and Senior Research Scientist, Nemours/A.I. duPont Hospital for Children (Wilmington, DE), the Journal provides early-stage screening techniques and tools that enable identification and optimization of novel targets and lead compounds for new drug development. Complete tables of content and a sample issue may be viewed on the ASSAY and Drug Development Technologies website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Applied In Vitro Toxicology, OMICS: A Journal of Integrative Biology, and Genetic Testing and Molecular Biomarkers. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is on the Mary Ann Liebert, Inc., publishers website.